COMBINATION THERAPY FOR REMOVING DETECTABLE HCV-RNS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION

摘要

There is disclosed the use of ribavirin, interferon alpha or a combination of ribavirin and interferon alpha for the manufacture of a pharmaceutical composition for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA by a method comprising administering an effective amount of ribavirin in association with an effective amount of interferon alpha, wherein the patient is one having failed to respond to a previous course of interferon alpha therapy. The compositions may be used in a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.